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Here, we demonstrate that the fractalkine (FKN)/
CX3CR1 system represents a regulatory mechanism
for pancreatic islet b cell function and insulin secre-
tion.CX3CR1 knockout (KO)mice exhibited amarked
defect in glucose and GLP1-stimulated insulin
secretion, and this defect was also observed
in vitro in isolated islets from CX3CR1 KO mice.
In vivo administration of FKN improved glucose
tolerance with an increase in insulin secretion.
In vitro treatment of islets with FKN increased intra-
cellular Ca2+ and potentiated insulin secretion
in both mouse and human islets. The KO islets
exhibited reduced expression of a set of genes
necessary for the fully functional, differentiated
b cell state, whereas treatment of wild-type (WT)
islets with FKN led to increased expression of these
genes. Lastly, expression of FKN in islets was
decreased by aging and high-fat diet/obesity, sug-
gesting that decreased FKN/CX3CR1 signaling could
be amechanism underlying b cell dysfunction in type
2 diabetes.
INTRODUCTION
The prevalence of type 2 diabetes has risen dramatically in the
United States and globally and has now reached epidemic
proportions (Olefsky and Glass, 2010). The etiology of this
disease involves both insulin resistance and decreased b cell
insulin secretion, and one typically needs both defects (two hit
hypothesis) in order to develop the hyperglycemic diabetic state
(Defronzo, 2009; Olefsky and Glass, 2010; Weir and Bonner-
Weir, 2004). b cell failure in type 2 diabetes is associated with
at least two major mechanisms: reduced overall b cell massand decreased insulin secretory function per b cell (Weir and
Bonner-Weir, 2004). In the prediabetic, insulin-resistant state,
islets respond to the increased insulin demand with enhanced
insulin secretion and increased b cell mass to generate com-
pensatory hyperinsulinemia and maintain relative euglycemia.
However, when type 2 diabetes emerges, b cell function and
mass are significantly decreased, with insufficient insulin secre-
tion to compensate for the insulin resistance, resulting in the
chronic hyperglycemic diabetic state. This b cell dysfunction is
largely manifested as impaired glucose-stimulated insulin secre-
tion (GSIS) and can be detected in the earliest stages of type 2
diabetes with complete loss of first phase GSIS (Defronzo,
2009; Weir and Bonner-Weir, 2004). On the other hand,
decreased b cell mass is usually not present at the time of diag-
nosis of type 2 diabetes (Rahier et al., 2008), suggesting that loss
of b cell mass is not responsible for the onset of type 2 diabetes
but rather is a consequence of diabetes.
Recently, it has been proposed that b cell dysfunction in dia-
betes is associated with progressive dedifferentiation of b cells
(Jonas et al., 1999; Weir and Bonner-Weir, 2004). This is accom-
panied by reduced expression of genes necessary for maintain-
ing the mature b cell phenotype, including PDX-1, Glut2, and
insulin, with increased expression of proliferative genes such
as c-myc (Jonas et al., 1999; Rahier et al., 2008). This may
provide a mechanism for increasing b cell mass, at the expense
of decreased b cell function.
Fractalkine (FKN; also known as CX3CL1 or neurotactin) is
a CX3C chemokine, and is expressed in neurons, endothelial
cells, hepatocytes, and vascular smooth muscle cells (Aoyama
et al., 2010; Cardona et al., 2006; Haskell et al., 1999; Lucas
et al., 2001; Zernecke et al., 2008). FKN is produced as
a membrane-bound protein and mediates cell-to-cell adhe-
sion and communication by binding to its cognate receptor
CX3CR1 (also known as GPR13) (Combadie`re et al., 2003; Imai
et al., 1997; Lesnik et al., 2003; Tacke et al., 2007; Teupser
et al., 2004; Zernecke et al., 2008). For example, membrane-
bound FKN promotes cell:cell adhesion and plays a role in theCell 153, 413–425, April 11, 2013 ª2013 Elsevier Inc. 413
attachment of monocytes/macrophages to CX3CR1-expressing
cell types (Haskell et al., 1999; Zernecke et al., 2008). In liver,
FKN expressed in hepatocyte and stellate cells is antifibrotic
and can suppress inflammatory activation of Kupffer cells
(Aoyama et al., 2010). In the brain, FKN mediates interactions
between neurons and glial cells (Cardona et al., 2006). A soluble
form of FKN is generated through proteolytic cleavage at the
base of the mucin-like stalk, mediated by ADAM 10 and ADAM
17 (Garton et al., 2001; Hundhausen et al., 2003), producing an
extracellular form of FKN that can regulate target cells by para-
crine mechanisms. Furthermore, cleaved soluble FKN enters
the circulation where it can have potential endocrine effects
(Shah et al., 2011).
In this study, we have discovered a regulatory pathway for the
FKN/CX3CR1 system in themodulation of b cell insulin secretory
function. We found that CX3CR1 knockout (KO) mice develop
hyperglycemia with reduced nutrient-stimulated insulin secre-
tion and that isolated islets from KO mice produce less insulin
in response to a variety of stimuli compared to wild-type
(WT) islets. Furthermore, in vivo FKN administration leads to
increased plasma insulin levels with improved glucose tolerance,
whereas in vitro FKN treatment of isolated islets directly
enhances b cell insulin secretion.
RESULTS
CX3CR1-Deficient Mice Exhibit Impaired Glucose
Tolerance with Reduced Insulin Secretion
Obesity causes inflammation and insulin resistance, and the
FKN/CX3CR1 system plays a role in monocyte attachment and
immune cell migration (Combadie`re et al., 2003; Hotamisligil
et al., 1995; Lee et al., 2010, 2011; Lesnik et al., 2003; Olefsky
and Glass, 2010; Tacke et al., 2007; Teupser et al., 2004). To
address the potential effect of this receptor on obesity-induced
inflammation, we studied lean and obese CX3CR1 KO mice.
The KO mice exhibited normal food intake, body weight gain,
and liver mass either on chow or high-fat diet (HFD) (Figures
1A–1C). Adipose tissue mass was the same between KO and
WT mice on chow diets, but was slightly lower in the KO mice
on HFD (Figure 1D). Interestingly, we found no evidence that
FKN or CX3CR1 play a role in macrophage accumulation in
adipose tissue or liver or in inflammation-induced insulin resis-
tance. For example, macrophage infiltration (Figure 1E) and
expression of macrophage marker genes, such as F4/80 and
CD11c (Figure 1F), were not altered in the adipose tissue of KO
mice. Moreover, CX3CR1 KO did not affect HFD-induction of
genes involved in inflammation (iNOS, MCP-1, and TNF-a) or
fibrosis (lysyl oxidase and collagen 1a) in adipose tissue (Fig-
ure 1F). Consistent with this, Lumeng also recently reported
that CX3CR1 deficiency is without effect on adipose tissue
macrophage content in HFD mice (Morris et al., 2012). Further-
more, the decrease in GLUT4 expression that typically occurs
on HFD was not attenuated by the CX3CR1 KO (Figure 1F), sug-
gesting that CX3CR1 KO does not affect insulin resistance.
Unexpectedly, both lean/chow-fed and obese/HFD CX3CR1
KO mice developed glucose intolerance compared to WT mice
upon oral glucose administration, and this effect was exacer-
bated in the obese state (Figure 2A). Despite the glucose intoler-414 Cell 153, 413–425, April 11, 2013 ª2013 Elsevier Inc.ance, these mice exhibited normal insulin sensitivity, as shown
by insulin tolerance testing (Figure 2B), suggesting that a defect
in insulin secretion was the cause of the hyperglycemia. To
assess this, we measured circulating insulin and C-peptide
levels during the oral glucose tolerance tests (OGTTs). Lean
chow-fed and obese HFD KO mice displayed decreased insulin
and C-peptide secretion with normal GLP1 levels (Figures 2C
and 2D; Figure S1 available online), compared to their WT
counter parts, indicating that CX3CR1 deficiency causes a b cell
insulin secretory defect. Interestingly, the glucose intolerance
and the defect in insulin secretion in the CX3CR1 KO mice was
more pronounced after an intravenous (IV) glucose challenge,
and the differences between WT and KO mice were quantita-
tively greater than after oral glucose (Figure 2E). Furthermore,
insulin secretion provoked by intraperitoneal (IP) arginine admin-
istration was reduced in both lean/chow-fed and obese/HFD
CX3CR1 KO mice (Figures 2F and 2G), further indicating that
CX3CR1 deficiency causes a b cell insulin secretory defect.
In complementary experiments, we injected anti-FKN anti-
bodies into mice to neutralize circulating FKN. This led to
decreased C-peptide levels and glucose intolerance (Figure 2H),
fully consistent with the results in the KO mice, indicating that
ongoing stimulation of CX3CR1 is required for normal insulin
secretion and glycemic control.
CX3CR1 KO Islets Display Reduced Insulin Secretion
with Decreased Expression of Genes Associated with
b Cell Function
To directly test b cell function and to determine whether the
in vivo insulin secretory defects are primary or secondary, we
carried out in vitro systems on isolated islets and Min6 cells.
First, to directly test the function of CX3CR1 in b cells, we
measured insulin secretion under static incubation conditions
by isolated islets obtained from chow and HFD WT and
CX3CR1 KO mice. As seen in Figure 3A, the KO islets exhibited
a marked decrease in GSIS that was more profound in islets ob-
tained from HFD KO mice (Figure 3B). Moreover, CX3CR1 KO
islets exhibited reduced insulin secretion in response to arginine
(Figure 3C), consistent with the in vivo results seen in Figure 2F.
To demonstrate the cell-autonomous effects of CX3CR1 on
GSIS in another way and to show that they are independent of
in vivo developmental issues, we used RNAi interference to
deplete CX3CR1 in Min6 cells in vitro (Figure 3D). Two different
anti-CX3CR1 siRNAs led to CX3CR1 knockdown, and both
attenuatedGSIS and abrogated FKN effects on insulin secretion.
We subsequently measured time-dependent insulin secretion by
WT andKO islets using perifusion analysis. The KO islets demon-
strated significantly lower insulin secretion rates compared to
WT in response to both high glucose and GLP1 stimulation (Fig-
ure 3E). Interestingly, oxygen consumption rates by WT and
CX3CR1 KO islets were comparable (Figure S2), implying that
CX3CR1 KO does not affect metabolic pathways or mitochon-
drial respiration. These in vitro experiments demonstrate that
the effects of CX3CR1 deletion are cell autonomous and not
secondary to other in vivo events. To test that the effect of
CX3CR1 KO is intrinsic to the islet in vivo, we transplanted
CX3CR1 KO and WT islets into the kidney capsule in strepto-
zotocin (STZ)-induced diabetic mice. As seen in Figure 3F,
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Figure 1. CX3CR1KOMice Exhibit Normal BodyWeight, Food Intake, Fat and Liver Mass, and Inflammatory andMetabolic Gene Expression
in Adipose Tissue
(A) Body weight change on HFD. Mean ± SEM, n = 20 for both WT and KO.
(B) Cumulative food intake on HFD. Food intake was measured from five different cages per group, and four mice were housed in each cage. Mean ± SEM.
(C) Liver mass. Mean ± SEM, n = 8 per group. NS, not significant. NCD, normal chow diet.
(D) Epididymal fat mass. Mean ± SEM, n = 8 per group. *p < 0.05.
(E) Immunohistochemistry analysis of epididymal adipose tissue using anti-F4/80 antibody. Representative figures were presented from the analyses of five
different mice per group.
(F) mRNA expression of inflammatory and metabolic genes in epididymal adipose tissue on NCD and HFD. Mean ± SEM, n = 5 per group. N, normal chow diet;
H, high-fat diet. AU, arbitrary unit.transplantation of WT islets had a greater effect to lower
glucose levels compared to transplantation of the KO islets.
This was further confirmed by measurements of insulin secre-
tion, which showed greater basal and insulin stimulated
insulin levels in the STZ mice transplanted with WT isletscompared to the STZ mice receiving the KO islets (Figure 3G).
Thus, the insulin secretory defect in CX3CR1 KO islets is
mediated by alterations in islet function independent of extraislet
mechanisms. Taken together, these data indicate that the b cell
FKN/CX3CR1 system is necessary for normal insulin secretoryCell 153, 413–425, April 11, 2013 ª2013 Elsevier Inc. 415
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Figure 2. CX3CR1 KO Mice Exhibit Impaired Glucose Tolerance due to Reduced Insulin Secretion
(A–D) CX3CR1 KO mice manifest impaired glucose tolerance with normal insulin sensitivity either on NCD (n = 11) or HFD (n = 12). Mean ± SEM.
(A) Oral glucose tolerance test. ##p < 0.01 WT-NCD versus KO-NCD; ###p < 0.001 WT-NCD versus KO-NCD; ***p < 0.001 WT-HFD versus KO-HFD. AUC, area
under the curve.
(B) Insulin tolerance test. *p < 0.05 WT-HFD versus KO-HFD; **p < 0.01 WT-HFD versus KO-HFD; NS, not significant.
(C) Plasma insulin (left), C-Peptide (middle), and GLP1 (right) levels of NCD mice during OGTT in (A). #p < 0.05; ##p < 0.01.
(D) Plasma insulin, C-peptide, and GLP1 levels of HFD mice during OGTT in (A). *p < 0.05; **p < 0.01.
(E) Intravenous glucose tolerance test (left) and plasma insulin level during IVGTT (right). Mean ± SEM, n = 4 per group.
(F and G) Plasma insulin and C-peptide levels of NCD (F) or HFD (G) mice during arginine tolerance test. Mean ± SEM, n = 8 per group. #p < 0.05; ##p < 0.01;
*p < 0.05; **p < 0.01.
(H) Fractalkine neutralization reduces insulin secretion and causes glucose intolerance in WT mice. FKN neutralizing antibody was injected IP to WT mice, and
30 min later, the mice were given oral gavage of glucose (2 g/kg) for GTT. Mean ± SEM, n = 10 per group. Left, plasma insulin level during GTT; right, GTT.
See also Figure S1.function in response to glucose, arginine, and GLP1, both in vitro
and in vivo.
To test whether the insulin secretory defect in CX3CR1 KO
islets is associated with altered gene expression, we performed
quantitative RT-PCR analyses. As shown in Figure 3H, the KO
islets expressed lower levels of genes involved in normal b cell
secretory function such as PDX-1, NeuroD, insulin, Glut2, and
urocortin3. Moreover, CX3CR1 KO islets exhibited reduced
expression of Connexin 36 (Figure 3H), a gap junction compo-
nent involved in b cell communication allowing the synchroniza-
tion of islet responses to metabolic signals (Calabrese et al.,
2003; Carvalho et al., 2010; Speier et al., 2007). Furthermore,
expression of some components of ATP-dependent potassium
channels (Kir6.2) or L-type voltage-gated calcium channels
(Cav1.2 and Cav1.3) was reduced in CX3CR1 KO islets although
this did not reach statistical significance (Figure S2). Thus, the416 Cell 153, 413–425, April 11, 2013 ª2013 Elsevier Inc.insulin secretory defect in CX3CR1 KO islets is associated with
reduced expression of genes involved in b cell function and
communication.
Histologic Studies of WT and CX3CR1 KO Islets
To determine whether CX3CR1 deletion affects islet develop-
ment, we conducted immunohistologic (IHC) studies and found
the expected effect of HFD to increase islet size (MacLean and
Ogilvie, 1955; Pick et al., 1998). However, under both chow and
HFD conditions, the islets were larger in the KOmice (Figure 4A).
Thiswas accompanied by a significant (p < 0.05) increase in b cell
mass, as measured bymorphometric analyses of insulin positive
islet cells (Figure 4B), and a corresponding increase in total
pancreatic insulin content (Figures 4C, S3A, and S3B). These
results show that CX3CR1 KO mice have sufficient b cells and
insulin, indicating that the in vivo phenotype is due to a defect
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Figure 3. CX3CR1 KO Islets Display Reduced Insulin Secretion with Lower Expression of Genes Involved in b Cell Function and
Communication
(A) Static GSIS test using primary mouse islets from WT and CX3CR1 KO mice fed NCD. Mean ± SEM, n = 6 per group. *p < 0.05.
(B) Static GSIS test using primary mouse islets from WT and CX3CR1 KO mice fed HFD for 10 weeks. Mean ± SEM, n = 6 per group.
(C) Static GSIS in the presence or absence of arginine (Arg; 10 mM) using primary mouse islets.
(D) Knockdown of CX3CR1 decreases GSIS in Min6 cells. Min6 cells were transfected with scrambled siRNA (Scrb) or two different CX3CR1 siRNAs (CX-1 and
CX-2). Forty-eight hours after transfection, GSIS was measured in the presence or absence of 100 ng/ml FKN (left panel), or quantitative real-time RT-PCR was
performed for CX3CR1 expression (right panel). **p < 0.01; ***p < 0.001.
(E) Perifusion experiment using islets from WT and CX3CR1 KO mice on NCD. Mean ± SEM, n = 5 per group. *p < 0.05; **p < 0.01.
(F and G) STZ-treatedmice transplanted withCX3CR1KO islets are more glucose intolerant thanmice transplanted withWT islets. Plasma glucose (F) and insulin
(G) levels during GTTs. Mean ± SEM, n = 6 per group (F), n = 5 per group (G).
(H) mRNA level of genes involved in b cell function and communication in islets from WT or CX3CR1 KO mice either on chow or HFD. mRNA level of each gene
was normalized to 18S rRNA level in the same sample. Mean ± SEM, n = 6 per group. *p < 0.05 WT-NCD versus KO-NCD or WT-NCD versusWT-HFD; **p < 0.01
WT-NCD versus KO-NCD or WT-NCD versus WT-HFD; #p < 0.05 WT-HFD versus KO-HFD. See also Figure S2.in coupling extracellular signals to the insulin secretory
machinery. Interestingly, the average b cell size was decreased
in the KO islets (Figure 4D), showing that the enhanced islet
mass was due to an increased number of smaller b cells. It has
been reported that smaller b cells display decreased GSIS
activity (Giordano et al., 1993; Pende et al., 2000). Consistent
with this, when we selected similar sized WT and CX3CR1 KO
islets for comparison, a small but significant decrease in insulin
content per islet was seen in theCX3CR1KOgroup (Figure S3C).
The histologic analysis also showed that the morphologic
features of the WT and KO islets, such as predominance of
insulin positive b cells in the core mantled by glucagon positive
a cells, was unaffected by the KO (Figure 4A). To assess mito-
chondria in CX3CR1 KO islets, we performed ultramicroscopic
analysis using electron microscopy. As seen in Figures 4E and
4F, morphology, size, number, and cristae abundance of mito-chondria were comparable in WT and CX3CR1 KO b cells,
consistent with the normal oxygen consumption rate in the
CX3CR1 KO islets (Figure S2). Formation of a proper microvas-
cular network within islets is essential for adequate insulin secre-
tion (Eberhard et al., 2010; Lammert et al., 2003), and because
FKN/CX3CR1 can modulate angiogenic pathways, we assessed
vascular density within the islets by staining for the endothelial
marker CD34. As seen in Figure 4G, CD34 staining was the
same in CX3CR1 KO and WT islets. Finally, total pancreas
mass in chow-fed or HFD CX3CR1 KO mice was comparable
to WT (Figure S3). Together, the results suggest that the defec-
tive insulin secretion in CX3CR1 KO mice was not due to gross
developmental defects, mitochondrial dysfunction, or defective
intraislet vascularization.
As shown in Figure 4H, IHC revealed that FKN and CX3CR1
are highly expressed in insulin-positive b cells in mouse islets.Cell 153, 413–425, April 11, 2013 ª2013 Elsevier Inc. 417
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Figure 4. CX3CR1 KO Mice Exhibit Increased b Cell Mass and Insulin Content
(A) Immunohistochemistry analysis of WT and CX3CR1 KO islets using anti-insulin (green) and antiglucagon (red) antibodies.
(B) b cell mass of WT and CX3CR1 KO mice on NCD. Mean ± SEM, n = 8 per group. *p < 0.05.
(C) Pancreatic insulin content. Mean ± SEM, n = 10 per group.
(D) Relative islet cell size of WT and CX3CR1 KO mice. Relative islet cell size was calculated by dividing b cell area by nuclei number. AU, arbitrary unit. Mean ±
SEM, n = 8 per group.
(E and F) Ultramicroscopic analysis of WT and CX3CR1 KO b cells. (E) Ultramicroscopic pictures of WT and CX3CR1 KOmouse islets on NCD. (F) Mitochondrial
length (upper left) and width (upper right), mitochondrial number per given area (lower left), and cristae abundance (lower right) was calculated using ImageJ
software. Mean ±SEM10 different EM pictures ofWT and KO islets, and at least twomitochondria located nearest to the center of each EMpicture were analyzed
for the morphometry. AU, arbitrary unit; NS, not significant.
(G) Vascular density in the islets of WT and CX3CR1 KO mice on NCD was analyzed by immunohistochemistry. Pancreatic sections were costained with anti-
CD34 (endothelial cell; green) and anti-insulin (b cell; red) antibodies, and the intensity of CD34-positive signals in the insulin-positive area was measured and
graphed in the right panel. Mean ± SEM, n = 6 (WT) and 8 (KO).
(H) Immunohistochemistry analysis of mouse islets using anti-CX3CR1 (red, on the left), anti-FKN (red, on the right), or anti-insulin (green) antibodies.
(I) Immunohistochemistry of human islet using anti-CX3CR1 (green) and anti-insulin (red), or anti-glucagon (red) antibodies.
See also Figure S3.
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Figure 5. FKN Enhances Insulin Secretion and Improves Glucose Tolerance in Mice in a CX3CR1-Dependent Manner
(A–C) WT and CX3CR1 KO mice (on NCD) were injected IP with glucose (2 g/kg) + FKN (40 mg/kg) or glucose + vehicle solution, and blood glucose and insulin
levels were measured at the indicated time points. Mean ± SEM, n = 6 (vehicle) or 7 (FKN).
(A) Glucose tolerance test in WT mice. *p < 0.05; **p < 0.01.
(B) Glucose tolerance test in CX3CR1 KO mice.
(C) Plasma insulin level during the GTTs.
(D) In vitro static GSIS studies using WT and KO islets in the presence or absence of mouse FKN (100 ng/ml). n = 6 per group.
(E) Perifusion experiment using primary mouse islets in response to the indicated levels of glucose, GLP1 (100 nM) and FKN (100 ng/ml). ***p < 0.001.
(F) Oxygen consumption rate in islets during the perifusion experiment in (E).
(G) In vitro static GSIS studies using human islets in the presence or absence of human FKN (100 or 400 ng/ml). n = 4. #p = 0.076; *p < 0.05 compared with lane 2.
See also Figure S4.Similarly, in human islets, CX3CR1 was expressed in b cells, but
not in glucagon-positive a cells (Figure 4I). RT-PCR analyses re-
vealed that both the receptor and FKN are expressed in isolated
human and murine islets, as well as in the Min6 (mouse) and
INS-1 (rat) b cell lines (Figure S3D).
In Vitro and In Vivo FKN Treatment
To provide a further test of our overall concept, we treated WT
and CX3CR1 KOmice with acute administration of the 84 amino
acid soluble chemokine portion of circulating mouse FKN. This
led to improved glucose tolerance in the WT mice (Figure 5A)but was without effect on glucose levels in the KO animals (Fig-
ure 5B). Importantly, in vivo FKN administration caused an
increase in insulin secretion in the WT mice, but not in the KOs
(Figures 5C and S4). We also treated isolated WT and CX3CR1
KO islets with soluble FKN and found a marked 58% increase
in GSIS in WT islets with no effect in the KO islets (Figure 5D).
FKN also significantly potentiated glucose plus GLP1-induced
insulin secretion in perifused primary mouse islets (Figure 5E)
but did not effect oxygen consumption (Figure 5F). These in vivo
and in vitro results demonstrate that FKN effects are direct and
are CX3CR1-dependent. To demonstrate the translatability ofCell 153, 413–425, April 11, 2013 ª2013 Elsevier Inc. 419
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Figure 6. FKN Stimulates Insulin Secretion by Increasing Intracellular Calcium Levels in a CX3CR1- and MEK-Dependent Manner
(A) GSIS test using primary mouse islets with or without pertussis toxin (PTX; 250 ng/ml), Wortmannin (Wort; 10 mM), or PD98059 (50 mM), in the presence or
absence of FKN (100 ng/ml). Mean ± SEM, n = 6 per group.
(B) GSIS test using Min6 cells with or without FKN (100 ng/ml) or U0126 (10 mM). Mean ± SEM.
(C–I) Intracellular calcium level in Min6 mouse b cells in the presence (C) and absence (D) of glucose, nimodipine (10 mM) (E), control antibody (F), anti-CX3CR1
neutralizing antibody (G), PTX (250 ng/ml) (H), or U0126 (10 mM) (I). Mean ± SEM.
(J) Intracellular cAMP level. Min6 cells were preincubated with isobutylmethylxanthine for 30 min and then treated with GLP1 (100 nM), forskolin (100 mM), or FKN
(100 ng/ml) at low (2.8 mM) or high (16.7 mM) glucose conditions for 30 min. Mean ± SEM.
(K) PKA enzymatic activity was measured in Min6 cells incubated in a low (2.8 mM) or high (16.7 mM) glucose condition for 15 min in the presence or absence of
GLP1 (100 nM) or FKN (100 ng/ml). Mean ± SEM.
(L) FKN stimulates expression of genes involved in b cell function. Primary mouse islets were incubated for 7 days with or without FKN (100 ng/ml), and mRNA
expression of PDX-1, NeuroD, Glut2, and HIF-1a was measured by quantitative real-time RT-PCR. Mean ± SEM. *p < 0.05.
(legend continued on next page)
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these findings to human b cells, we conducted studies in isolated
human islets. As seen in Figure 5G, treatment of human islets
with human FKN led to a dose responsive increase in GSIS
with a 65% increase at the maximal concentration. Thus, the
potentiating effects of FKN are quantitatively similar in mouse
and human islets.
Effects of FKN Treatment on b Cell Signaling
To determine the pathways by which FKN/CX3CR1 regulates
insulin secretion, we measured GSIS in isolated islets treated
with inhibitors of Gai (pertussis toxin), PI3K (Wortmannin), and
MEK (PD98059) at low and high glucose levels. FKN-stimulated
insulin secretion was inhibited by pertussis toxin and the MEK
inhibitor, but not by Wortmannin (Figure 6A). Consistent with
these results, FKN stimulated ERK phosphorylation in a Gai-
and MEK-dependent fashion (Figure S5), and inhibition of MEK
suppressed FKN potentiation of glucose and GLP1-induced
insulin secretion in Min6 cells (Figure 6B). As seen in Figures
6A and 6B, FKN-stimulated insulin secretion was not evident at
2.8 mM glucose and only occurred when sufficient glucose
was provided (16.7 mM), consistent with Figure 5, which shows
that FKN is not a direct insulin secretagogue but rather potenti-
ates the effects of other insulin secretory signals such as glucose
and GLP1.
In b cells, calcium signaling is a critical component of the
insulin secretory process (Seino et al., 2011). Because FKN
has been shown to increase cytoplasmic calcium levels in
macrophages and fibroblasts (Fong et al., 2002; Imai et al.,
1997), we measured the FKN effect on intracellular calcium at
low or high glucose conditions in Min6 cells. As shown in Figures
6C and 6D, FKN increased intracellular calcium levels with high
glucose (Figure 6C) but was without effect in the absence of
glucose (Figure 6D). Interestingly, inhibition of calcium influx by
the L type calcium channel inhibitor, nimodipine, blocked both
glucose- and FKN-induced intracellular calcium increase,
implying that calcium influx is necessary for the FKN effect (Fig-
ure 6E). CX3CR1 neutralization with a specific antibody blocked
the FKN-induced intracellular calcium increase, showing that
this effect of FKN is mediated by CX3CR1 activation (Figures
6F and 6G). Moreover, the effect of FKN on intracellular calcium
was blocked by treatment with the pertussis toxin or the MEK
inhibitor (Figures 6H and 6I), suggesting that a Gai- and MEK-
mediated effect plays a mechanistic role in FKN-stimulated
insulin secretion. Interestingly, theMEK inhibitor attenuated argi-
nine-induced intracellular Ca2+ increase and insulin secretion in
Min6 cells, but only in the presence of glucose (Figure S6).
Part of the effect of glucose and GLP1 to augment insulin
secretion involves increases in cyclic AMP levels. Consequently,
we measured glucose, GLP1, and forskolin stimulated cyclic(M) ICER-1 mRNA expression in WT and CX3CR1 KO islets. Mean ± SEM.
(N) Palmitate-induced ICER-1 expression is suppressed by FKN in Min6 cells. M
(O) GSIS by Min6 cells treated with palmitate (Pal; 0.4 mM) for 48 hr in the prese
(P) FKN represses binding of ICER-1 toNeuroD promoter. Min6 cells were incubat
FKN (100 ng/ml). After 48 hr, the cells were fixed and subjected to chromatin im
(Q) Suppressive effect of FKN on ICER-1 expression is abolished byMEK inhibitor
or absence of FKN (100 ng/ml) or U0126 (10 mM). After 48 hr, cells were harvest
See also Figures S5, S6, and S7.AMP levels with and without FKN in Min6 cells (Figure 6J). Inter-
estingly, FKN was without effect on cyclic AMP concentrations,
and consistent with this, protein kinase A (PKA) activity was also
unaffected by FKN treatment (Figure 6K).
We also assessed longer term effects of FKN on islet gene
expression. Seven days of chronic in vitro treatment of islets
with FKN led to increased expression of PDX1, NeuroD, HIF-
1a, and insulin (Figure 6L), and these genes were all downregu-
lated in the CX3CR1 KO islets (Figure 3H). Recently, it has been
shown that b cell dysfunction induced by HFD or free fatty acid
treatment is, at least partially, mediated by the induction of
inducible cyclic AMP early repressor (ICER-1) (Cho et al., 2012;
Favre et al., 2011; Hussain et al., 2000; Zhou et al., 2003). Inter-
estingly, ICER-1 expression was highly induced in the CX3CR1
KO islets (Figure 6M), and FKN treatment abolished palmitate-
induced and increased ICER-1 mRNA in Min6 cells (Figure 6N).
Concomitantly, FKN treatment prevented chronic palmitate-
mediated inhibition of GSIS (Figure 6O). Moreover, using chro-
matin immunoprecipitation experiments, we found that FKN
treatment blocked the effect of palmitate to induce binding of
ICER-1 to the NeuroD promoter in Min6 cells (Figure 6P). These
results suggest that one aspect of the FKN effect on b cells might
involve regulation of genes necessary for the insulin secretory
machinery, and this could be partially mediated by ICER-1
suppression. To test whether FKN regulation of ICER-1 is asso-
ciated with MEK signaling pathways, we incubated Min6 cells
with palmitate in the presence or absence of FKN and the MEK
inhibitor. As shown in Figure 6Q, FKN treatment suppressed
palmitate-induced ICER-1 expression, whereas it increased
expression of NeuroD, PDX-1 and Glut2; all of the FKN effects
were abolished by the MEK inhibitor. These results suggest
that FKN suppresses ICER-1 expression through a MEK-depen-
dent pathway.
b cell failure in type 2 diabetes is associated with loss of b cell
volume as well as loss of GSIS (Prentki and Nolan, 2006). FKN
has been shown to increase survival of microglial cells and
vascular smooth muscle cells through a CX3CR1-PI3K-Akt-
dependent pathway (Boehme et al., 2000; Chandrasekar et al.,
2003). Therefore, we assessed whether FKN has in vitro effects
on b cell growth and survival. As shown in Figure S7A, FKN pre-
vented b cell apoptosis induced by chronic palmitate treatment,
and this effect was comparable to that observed with GLP1
treatment. Moreover, FKN increased the number of viable cells,
which was reduced by chronic palmitate treatment (Figures S7B
andS7C). Interestingly, the increase in viable cell number by FKN
was comparable to the degree of inhibition of b cell apoptosis,
suggesting that the increase of b cell number was due to reduced
apoptosis, rather than increased proliferation. Consistent with
this, CX3CR1 KO did not change the number of Ki67 positiveean ± SEM.
nce or absence of FKN (100 ng/ml).
ed in serum-freemedia in the presence or absence of palmitate (100 mM) and/or
munoprecipitation with anti-iCER-1 antibody.
(U0126). Min6 cells were incubated with palmitate (Pal; 0.4mM) in the presence
ed and subjected to quantitative real-time PCR.
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Figure 7. FKN Expression Is Decreased by
Aging and HFD in Islets
(A) FKN mRNA expression in 7-week-old (7w)-
NCD (N), 24-week-old (24w)-NCD, or 24-week-
old-HFD mice. *p < 0.05 24w-NCD versus
24w-HFD. FKN mRNA level was normalized to 18S
rRNA level in each sample. Mean ± SEM, n = 6
per group.
(B) FKN mRNA expression in 7-week-old (7w)-
NCD (N; n = 5), 1-year-old (1y)-NCD (n = 8), or
1-year-old-HFD (H; n = 6) mice. Mean ± SEM.
*p < 0.05 7w-NCD versus 1y-NCD or 7w-NCD
versus 1y-HFD.
(C) FKN protein expression levels were measured in
aliquots of the samples used in (B). FKN protein
levels were normalized by total protein concentra-
tion. Mean ± SEM. *p < 0.05 7w-NCD versus 1y-
NCD; **p < 0.01 7w-NCD versus 1y-HFD; #p < 0.05
1y-NCD versus 1y-HFD.
(D) FKN mRNA expression is decreased in in vitro
expanded human b cells. mRNA levels of FKN and
CX3CR1 were analyzed by Affymetrix GeneChip
microarrays (Kayali et al., 2007; Kutlu et al., 2009) in
freshly isolated human islets (Islet) or in vitro
expanded islets (Exp) as described in Experimental
Procedures. Mean ± SEM.proliferating cells on both chow andHFD (Figure S7D). FKN stim-
ulated Akt phosphorylation, which was inhibited by Wortmannin
(Figure S7E). Moreover, the preventative effect of FKN against
palmitate-induced apoptosis was inhibited by Wortmannin (Fig-
ure S7F), suggesting that the antiapoptotic effect of FKN oper-
ates through a PI3K-Akt-dependent mechanism.
Islet FKN Expression Is Decreased by Aging and HFD
Aging and obesity are major risk factors for b cell dysfunction.
We found that mRNA and protein levels of FKN were decreased
in islets from old or HFD/obese/diabetic mice (Figures 7A–7C).
On the other hand, CX3CR1 expression was not affected by
aging or HFD (data not shown). Interestingly, FKN expression
was not decreased after 24 weeks of age on normal chow but
was significantly decreased in the same age mice by 16 weeks
of HFD, suggesting that HFD accelerates the decreased FKN
expression in aging. Ex vivo expansion of b cells causes dediffer-
entiation and loss of b cell function. To evaluate whether reduced
FKN/CX3CR1 signaling correlates with b cell differentiation
status, we compared FKN and CX3CR1 mRNA levels in human
islets and ex vivo expanded human b cells. As seen in Figure 7D,
FKN, but notCX3CR1, expression was significantly decreased in
expanded human islet-derived cells. We previously demon-
strated that expanded human islet cells dedifferentiate and go
through an epithelial to mesenchymal transition in vitro (Kayali
et al., 2007; Kutlu et al., 2009), such that the resulting expanded
cells are closer in phenotype to mesenchymal stem cells than to
the original endocrine cells.
DISCUSSION
Here, we describe a mechanism for regulating b cell function
through the FKN/CX3CR1 system. CX3CR1 KO mice develop422 Cell 153, 413–425, April 11, 2013 ª2013 Elsevier Inc.glucose intolerance on both chow and HFD due to decreased
insulin secretion. Neutralization of circulating FKN by in vivo
administration of anti-FKN antibodies recapitulated this effect,
causing glucose intolerance with diminished insulin secre-
tion, demonstrating that FKN is necessary for ongoing mainte-
nance of circulating insulin levels. The impaired insulin
secretion represents a primary b cell defect, because isolated
islets from CX3CR1 KO mice exhibited impaired GSIS
compared to WT islets and CX3CR1 KO islets transplanted
into STZ-induced diabetic mice had an attenuated ability to
correct the diabetic state compared to transplantation of WT
islets. Finally, in vivo administration of FKN treatment led to
improved glucose tolerance with increased insulin secretion
and in vitro treatment directly caused increased GSIS in iso-
lated mouse and human islets. In contrast, FKN was without
effect on insulin secretion in CX3CR1 KO mice or in islets
from KO animals. Taken together, these studies reveal a regula-
tory system for b cell insulin secretion, suggesting that a FKN-
based biotherapeutic, or a small molecule CX3CR1 agonist,
could be a useful therapeutic tool in the treatment of type 2
diabetes.
CX3CR1 is the unique receptor for FKN and FKN is the
only known ligand for this G protein-coupled receptor (Imai
et al., 1997; Zernecke et al., 2008). FKN is expressed as a
membrane-bound protein, which can interact with CX3CR1 on
adjacent cells to facilitate cell:cell adhesion and communication
(Haskell et al., 1999; Zernecke et al., 2008). The extracellular
domain of FKN can be cleaved through the action of the extracel-
lular proteases Adam10 and 17 to produce a soluble form of FKN
(Garton et al., 2001; Hundhausen et al., 2003). Soluble FKN can
exert paracrine effects in the extracellular space and can also
enter the circulation to potentially cause endocrine effects on
distant tissues (Shah et al., 2011).
It has recently been reported that two single-nucleotide poly-
morphisms (T280M and V249I), located in the coding sequence
of human CX3CR1, are associated with an increased incidence
of type 2 diabetes and metabolic syndrome (Shah et al., 2011;
Sirois-Gagnon et al., 2011). These CX3CR1 gene variants result
in lower FKN binding affinity, consistent with the view that the
FKN/CX3CR1 system plays a beneficial role in the maintenance
of proper insulin secretion and glycemic control. On the other
hand, circulating levels of soluble FKN are not decreased in
type 2 diabetic patients and, in fact, are slightly higher than
controls (Shah et al., 2011). This raises the question as to why
b cell function is defective in the face of increased circulating
FKN levels in type 2 diabetes. Certainly, b cell dysfunction in dia-
betes is a complicated, multi-factorial process, involving factors
in addition to FKN/CX3CR1. However, several other possibilities
also come tomind. First, it is possible that the local expression of
soluble FKN is dominant over the circulating levels and that
intraislet FKN levels are low in type 2 diabetes, similar to what
we have observed in aging and HFD/obese islets in mice.
Second, CX3CR1 signaling could be impaired in diabetic b cells
leading to FKN resistance. Finally, although FKN levels are not
decreased, it is possible that CX3CR1 expression is decreased
in b cells from type 2 diabetes patients, although we did not
observe this in islets from aging or HFD/obese mice. Clearly,
future studies will be necessary to explore these issues.
Our in vitro studies demonstrate that FKN is not a direct
insulin secretagogue because it does not enhance insulin secre-
tion in the absence of glucose or at low glucose concentrations.
Instead, FKN only exerts its effects by potentiating GSIS-, argi-
nine-, or GLP1-mediated insulin secretion. Our in vitro studies
show that the acute effects of FKN on insulin secretion are not
due to changes in mitochondrial function, cyclic AMP levels,
or increased PKA activity. In the presence of glucose, FKN
causes an increase in intracellular calcium levels through
a MEK-dependent mechanism. Combined with the fact that
CX3CR1 deletion impairs the insulin secretory response to
arginine, this suggests that the effects of FKN on insulin secre-
tion are exerted at a downstream step common to several stim-
ulatory inputs, most likely involving MEK-dependent calcium
mobilization events.
Our data demonstrate that FKN has acute effects to potentiate
GSIS- and GLP1-stimulated insulin secretion, but it is also
possible that FKN has chronic effects on b cell function as
well. Thus, CX3CR1 KO islets display decreased expression of
a set of genes characteristic of normal, fully functioning b cells,
including PDX1,NeuroD,GLUT2, urocortin3, andCX36. Further-
more, chronic FKN treatment of WT islets leads to increased
expression of these genes. Thus, one could take the view that
CX3CR1 deletion, with ablation of FKN signaling, produces
b cells that are partially dedifferentiated. Indeed, the KO islets
are characterized by increased total cell mass due to increased
numbers of smaller b cells, and it has been reported that reduced
b cell size is associated with impaired insulin secretory function
(Giordano et al., 1993; Pende et al., 2000). Along these lines, we
found that ICER-1 is induced inCX3CR1 KO islets, whereas FKN
treatment of Min6 cells suppresses palmitate-induced ICER-1
expression. ICER-1 is a transcriptional repressor that can inhibit
genes associated with the normal differentiated b cell functionalstate. It has been shown that ICER-1 is induced by saturated
fatty acids, oxidized LDL, hyperglycemia, and high-fat diet,
and ICER-1 induction can cause b cell dysfunction by inhibiting
expression of CX36, as well as components of the insulin
secretory machinery as exemplified in Figure 3 (Favre et al.,
2011; Hussain et al., 2000; Zhou et al., 2003). This suggests
that increased ICER-1 expression in CX3CR1 KO b cells is
mechanistically linked to a more chronic state of b cell dys-
function. In this context, it is important to note that in vitro
siRNA-mediated knockdown of CX3CR1 in Min6 cells caused
decreased GSIS, suggesting that the in vivo decrease in insulin
secretion in the KOmice was not due to an in vivo b cell develop-
mental defect.
Together, these studies describe a novel pathway regulating
b cell secretory function in which FKN stimulates CX3CR1 to
promote increased insulin secretory responses. CX3CR1 defi-
ciency mimics some of the b cell abnormalities observed in dia-
betic islets, and FKN treatment restores these defects toward
normal. In mice, aging and the HFD/obese hyperglycemic state
are associated with decreased islet FKN expression. Thus,
attenuation of FKN/CX3CR1 system could potentially underlie
some of the defects in diabetic islets. Furthermore, a FKN-based
biotherapeutic, or a small-molecule CX3CR1 agonist, could have
potential utility in the treatment of type 2 diabetes.
EXPERIMENTAL PROCEDURES
Animals and Treatments
Seven-week-old male C57BL/6N and CX3CR1 knockout mice were
purchased from Taconic (USA). Glucose tolerance test (GTT) and insulin toler-
ance test (ITT) results from the CX3CR1 KO mice were confirmed in
CX3CR1gfp/gfp knockin mice obtained from Jackson Laboratory (USA). Oral
glucose tolerance test and intraperitoneal (IP) insulin tolerance test were per-
formed as described previously (Lee et al., 2010, 2011). For arginine tolerance
test, the mice were fasted for 6 hr and basal blood samples were taken,
followed by IP injection of 1 g/kg arginine. All animal procedures were in
accordance with the research guidelines for the use of laboratory animals of
University of California, San Diego. Detailed protocols are described in the
Extended Experimental Procedures.
Plasma Protein Measurements
Plasma insulin (ALPCO, USA), C-peptide (ALPCO), GLP1 (active 7-36 GLP1;
Millipore, USA), and fractalkine (R&D Systems, USA) levels were measured
by ELISA.
Islet Transplantation
A single aliquot of 200 freshly isolated islet equivalents was transplanted into
the left kidney capsule of the recipient mice. Please see the Extended Exper-
imental Procedures for details.
Measurement of Insulin Secretory Response from Isolated Islets
For dynamic resolution of insulin secretory response, islets were perifused at
37C, 5% CO2 in a system comprised of a pump, gas equilibrating system,
and islet chamber, as described previously (Sweet et al., 2004). For static
GSIS assays, 20 mouse islets or 100 islet equivalent (IEQ) human islets
were incubated for 2 hr in low glucose media at 37C, 5% CO2, and then incu-
bated for 60 min or 75 min with 2.8 mM or 16.7 mM glucose in the same condi-
tions. Please see the Extended Experimental Procedures for details.
Intracellular Calcium Level Measurement
The cytoplasmic-free calcium ion concentration in Min6 cells was measured
by fura-2 fluorescence ratio digital imaging. Please see the Extended Experi-
mental Procedures for details.Cell 153, 413–425, April 11, 2013 ª2013 Elsevier Inc. 423
cAMP Level Measurement
Intracellular cAMP level of Min6 cells was measured using Bridge-it cAMP
assay kit (Mediomics, USA).
Electron Microscopy
Scanning electron micrographs were taken using Phillips 12 XL30 ESEM in an
environmental mode at Calit2-Nano3 facility. Please see theExtended Experi-
mental Procedures for details.
Human Islet and In Vitro b Cell Expansion
The human islet and b cell samples were prepared and analyzed as described
previously (Kayali et al., 2007; Kutlu et al., 2009). Please see the Extended
Experimental Procedures for details.
Statistics
The results are shown as means ± SEM. All statistical analysis was performed
by Student’s t test or ANOVA in Excel (Microsoft); p < 0.05 was considered
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2013.03.001.
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